Comparative Pharmacology
Head-to-head clinical analysis: CO GESIC versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO GESIC versus ROXIPRIN.
CO-GESIC vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination